RAAS inhibition in patients with kidney disease: Balancing the benefits and risks
Although RAAS inhibition reduces proteinuria and hypertension in cardio-renal patients, it is associated with increased risk of hyperkalemia. Prof. Rossignol shares data on the addition of patiromer in patients using spironolactone for the management of CKD with resistant hypertension.
Video navigation menu
- Serum potassium levels associated with adverse outcomes across eGFR levels 01:16
- Real-world data on management of recurrent hyperkalemia and use of RAAS inhibitors 02:20
- Double challenge of resistant hypertension and CKD 04:42
- The Amber trial: does patiromer enable persistent use of spironolacton in patients with hypertension and CKD? 06:10
This lecture by prof. Patrick Rossignol was part of a CME accredited symposium "RAASi and Hyperkalemia in Cardiorenal Disease: Opportunities for optimizing outcomes" held during ERA-EDTA 2019 in Budapest, Hungary.
Prof. Patrick Rossignol, MD - Professor of Therapeutics at the University of Lorraine, France.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Vifor Fresenius Medical Care Renal Pharma.
This is available as accredited online CME for members. Click the button below to enroll:Enroll